PerkinElmer
check quantity

CD28/CD86 (human) AlphaLISA Binding Kit, 500 Assay Points

The AlphaLISA® human CD28/CD86 binding kit is designed for the detection of binding activity between human CD28 and CD86, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
AL3131C
500 Assay Points
2529.00 USD
 
more
AL3131F
5,000 Assay Points
12600.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

AlphaLISA features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad range of affinities
  • High avidity
  • Results in less than 3 hours
  • Half the time of an ELISA assay

AlphaLISA® technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

The AlphaLISA human CD28/CD86 binding kit allows determination of cross-reactivity of human anti-CD28 or CD86 reagents with cynomolgus proteins, as well as development or screening of novel human CD28 and CD86 reagents that block the binding of this interaction. Using the AlphaLISA human CD28/CD86 binding assay, small molecule antagonists or large molecule therapeutics and blocking antibodies can be screened in microplate format.

Specifications

Assay Target CD28, CD86
Assay Target Class Protein
Assay Technology Alpha
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Immuno-oncology
Unit Size 500 Assay Points
Resources, Events & More
  • All

Application Note

Screening for Inhibitors of PD-1 and PD-L1 Binding with AlphaLISA Technology

Many tumor cells, which under normal, healthy conditions would be recognized by the body’s T cells and thereby targeted for destruction, have developed ways to evade the host immune system by taking advantage of immune checkpoint pathways. Among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T-cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Inhibitors that block PD-1/PD-L1 complex formation lead to increased activation of T-cells and immune system functions, allowing the body’s immune system to identify and attack tumor cells. So far, several anti-PD-1 or PD-L1 monoclonal antibodies have been developed to treat a variety of cancers, including non-small cell lung carcinoma (NSCLC), metastatic melanoma and renal cancer. The promise of therapeutically exploiting this pathway has created a need for more robust, straight-forward assays to identify and qualify potential inhibitors which interrupt PD-1/PD-L1 binding. Find out how AlphaLISA® technology provides a simple, homogenous, straightforward method for detecting PD-1/PD-L1 binding.

PDF 1 MB

Brochure

Alpha Technology Solutions

Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.

PDF 4 MB
Drug Discovery Screening Solutions Brochure

Info on PerkinElmer's complete solutions for high-throughput and phenotypic screening.

PDF 4 MB